Navigation Links
Draft National Policy on Sight-saving Drugs unacceptable

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is unacceptable concludes the July issue of Drug and Therapeutics Bulletin (DTB).

But that is what the National Institute for Health and Clinical Excellence (NICE), the body responsible for guiding the NHS on which treatments to use, is proposing.

Ranibizumab (Lucentis) and pegaptanib (Macugen) are licensed in the UK for the treatment of neovascular (wet) age-related macular degeneration. A third drug bevacizumab (Avastin) is also used, but not licensed for the condition.

In wet age-related macular degeneration, in which fine central vision is progressively lost, new blood vessels grow beneath the retina, a process stimulated by vascular endothelial growth factor (VEGF). All three drugs potentially block the effects of VEGF.

Wet age-related macular degeneration is the third most common cause of blindness worldwide. It affects around 2.3% of over-65s in Europe. In the UK around 26,000 people develop it each year and 245,000 are blind or visually impaired because of it.

After a thorough examination of published clinical trial data, DTB concludes that there is good evidence that both ranibizumab and pegaptanib prevent further deterioration in vision in most patients. Ranibizumab improved vision in a third.

The NICE draft guidance on use of ranibizumab and pegaptanib was published in June. It recommends ranibizumab for only about 20 per cent of patients with wet age-related macular degeneration, restricting its use to those in whom both eyes are affected and then to the better seeing eye.

Final guidance is due in September.

DTB says: We believe that policies that dictate that patients must go blind in one eye before being given treatment for the other are unacceptable.

It continues: Pegaptanib and ranibizumab need to be made available for use thr oughout the NHS, as is the case in Scotland. In the absence of such national arrangements elsewhere in the UK, NHS commissioners need to work with local clinicians to ensure that the benefits of these drugs are made available to as many patients as possible.

NICE has not issued draft guidance on bevacizumab, but many primary care trusts recommend its use because it is cheaper than pegaptanib and ranibizumab.

DTB says that bevacizumab might provide a lower cost alternative, but cautions that there is as yet no robust evidence of its safety and effectiveness in the treatment of macular degeneration. Therefore, we cannot recommend such use outside of clinical trials.


'"/>




Related medicine news :

1. OPPI Opposes Draft National Pharmaceuticals Policy
2. Smoking Ban Draft Is Put For Consultation
3. Kerala Drafts a New Health Tourism Policy
4. National Lung Study in the process
5. Indian Nationals with Foreign Medical Degrees can now practice in India
6. Hepatitis B Vaccine To Be Included In National Immunization Programme
7. UK Govt Says On Course For National Chlamydia Screening
8. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
9. India extends National TB Control Program
10. President and Founder of National Obesity Forum Resigns
11. Hwang Woo Suk Suspended By Seoul National University
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... ... May 06, 2016 , ... Canadian author Mark Black is a speaker, author, ... the Heart" around the world … with the help of his publisher Strategic Book Group ... Black lay in a hospital bed waiting for a miracle: He needed a heart and ...
(Date:5/6/2016)... ... ... Multiple award winning plumbing company in San Diego, Bill Howe ... values of exceptional customer service, quality work at reasonable rates, and giving back to ... Diego plumbing, and other services including heating & air conditioning and restoration & flood ...
(Date:5/6/2016)... ... 2016 , ... In honor of Military Spouse Appreciation Day ... the National Military Family Association, a nonprofit that works to strengthen and protect ... recipient of 2016. , “Being awarded this scholarship by Career Step, is ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... ReportsnReports.com adds "Cochlear Implants ... database. The report provides comprehensive information on the ... at various stages of development. The report reviews ... It also provides information about clinical trials in ... start and end dates, and, the number of ...
(Date:5/6/2016)... ORANGE COUNTY, Calif. , May 6, 2016  Ampronix is excited to announce that ... 4K Ultra HD 3MOS. First launched last November, the UHD camera was released to the ... ... ... The finely crafted GP-UH532 ...
(Date:5/6/2016)... According to a new ... (Sso-PCR, Ssp-PCR, NGS, Sanger,s Sequencing), Products & Services ... (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", ... to reach USD 753.9 Million by 2021 from ... of 7.1% from 2016 to 2021. ...
Breaking Medicine Technology: